Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (NASDAQ: PODD) is a Massachusetts-based medical device company known for its Omnipod tubeless insulin pump platform, which is designed to simplify life for people with diabetes. The Insulet news feed on Stock Titan aggregates company announcements, earnings updates, product milestones, and strategic disclosures that shape the PODD stock narrative and the evolution of automated insulin delivery.
Investors and observers can follow news on the Omnipod Insulin Management System and the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors to automate insulin dosing without multiple daily injections or fingersticks. Company releases highlight regulatory clearances, such as FDA 510(k) decisions for Omnipod 5 algorithm enhancements, as well as technology demonstrations at events like the Consumer Electronics Show, where Insulet presents its vision for “liveable technology” in connected health.
The PODD news stream also covers quarterly and annual financial results, long-range financial outlooks, and Investor Day presentations in which Insulet outlines its growth strategy in automated insulin delivery markets. Additional updates include sustainability initiatives like the expansion of the U.S. Pod recycling program, collaborations such as the Omnipod Mango color partnership with Pantone, and governance developments including executive and board appointments.
By reviewing Insulet news on this page, readers can track how the company’s Omnipod platform, innovation roadmap, financial performance, and corporate actions intersect. Bookmark this feed to monitor new product features, regulatory developments, strategic events, and other disclosures that may be relevant to understanding PODD as both a medical technology business and a publicly traded stock.
Insulet (NASDAQ: PODD) will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. PT. A live webcast and replay will be available on the Insulet investor relations website.
The presentation covers company updates and the Omnipod product platform; webcast access: investors.insulet.com/events.
Insulet (NASDAQ: PODD) announced it will report first quarter 2026 financial results on Wednesday, May 6, 2026, before the opening of U.S. markets. Management will host a conference call at 8:00 a.m. Eastern Time that day and a live webcast will be available.
Investors can join via the Investor Relations "Events and Presentations" page, or by dialing the provided domestic and international numbers using passcode 5904836. The webcast will be archived for future replay. The company markets the Omnipod tubeless insulin pump platform and Omnipod 5 automated insulin delivery system.
Insulet (NASDAQ: PODD) appointed Mike Panos as Executive Vice President, Chief Commercial Officer, effective March 30, 2026. Mr. Panos will lead the company’s global commercial organization and report to President and CEO Ashley McEvoy as a member of the Executive Leadership Team.
He brings 30 years of medical-technology commercial leadership, most recently at Stryker, and will focus on commercial strategy, market access, and expansion into new patient populations and care settings to support growth of the Omnipod platform.
Insulet (NASDAQ: PODD) initiated a voluntary Medical Device Correction on March 12, 2026 for specific Omnipod 5 Pod lots distributed in the U.S. Certain Pods may have a small tear in internal tubing causing insulin to leak and possible under-delivery.
Insulet reported 18 serious adverse events including hospitalization and DKA, no deaths, updated manufacturing controls, said affected pods are ~1.5% of annual production, and offers free replacement Pods via omnipod.com/check-pods.
Insulet (NASDAQ: PODD) presented EVOLUTION 2 feasibility study results for its investigational Omnipod fully closed-loop (FCL) automated insulin delivery system for adults with type 2 diabetes.
In 24 diverse adults using the final algorithm with no boluses, average time in range reached 68% (a 24% improvement versus injection therapy); median time below range was 0.14%. No severe hypoglycemia or DKA occurred. Over 90% of participants continued into the extension. The company plans a pivotal EVOLVE study in 2026, a 510(k) filing in 2027, and commercial launch in 2028.
Insulet (NASDAQ: PODD) will present EVOLUTION 2 results for its Omnipod fully closed-loop automated insulin delivery system for adults with type 2 diabetes at ATTD 2026 in Barcelona, March 11–14, 2026.
The company will host a symposium on March 11 (2:40–4:10 p.m. CET, Hall 112), present seven posters/orals including e-Poster EP070, and offer product demos, an immersive education HUB, live podcasts, and a March 13 webcast recap at 3:00 PM CET.
Insulet (NASDAQ: PODD) reported strong Q4 2025 and full‑year results: Q4 revenue $783.8M (+31.2%) and FY 2025 revenue $2.7B (+30.7%); gross margin improved to 72.5% in Q4 and 71.6% for the year. The company announced a $350M increase in its share repurchase authorization and provided 2026 guidance with mid‑20s revenue growth in constant currency.
Insulet highlighted >600,000 estimated active Omnipod users, international expansion, FDA algorithm enhancements for Omnipod 5, and stronger operating cash flow and free cash flow versus prior year.
Insulet (NASDAQ: PODD) launched the Omnipod 5 Automated Insulin Delivery System and the new Omnipod Discover data platform in the Middle East on February 5, 2026.
Omnipod 5 is commercially available in Saudi Arabia, Kuwait, Qatar, and the UAE, compatible with Abbott FreeStyle Libre 2 Plus and Dexcom G7 (Dexcom G7 only in Qatar), and indicated for ages two and older. Omnipod Discover provides retrospective glucose and insulin delivery analytics. Omnipod 5 is now available in 19 countries, with launches planned in Spain (2026), Greece and Croatia (1H 2027).
Insulet (NASDAQ: PODD) will report fourth quarter and full year 2025 financial results on February 18, 2026 before market open. Management will host a conference call the same day at 8:00 a.m. ET. A live webcast will be available on the company's Investor Relations site under "Events and Presentations" and an archived replay will be posted. Dial-in numbers for domestic and international access and passcode 5904836 are provided.
Insulet is the maker of the Omnipod tubeless insulin pump platform and Omnipod 5 automated insulin delivery system.
Insulet (NASDAQ: PODD) will debut at CES 2026 to showcase its “liveable technology” vision and Omnipod automated insulin delivery. The company will host a panel and an immersive booth demonstrating how Omnipod 5 aims to reduce the mental load of diabetes through seamless automation and human-first design.
Key details: Panel on January 6, 3:25 PM–4:05 PM PT at Venetian, Level 4, Marcello 4404; Booth at Venetian Expo, Level 2, Booth #54412. Activities include product demonstrations, specialist interactions, and real-user stories highlighting connected-health innovations.